Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 6/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2919200 | 0.99 | L3MBTL1 (0.39) | L3MBTL1DDB1CRBNALDH1A1HPGD | |
| SCHEMBL4938342 | 0.90 | ALDH1A1 (0.42) | L3MBTL1DDB1CRBNALDH1A1CYP1A2 | |
| SCHEMBL3593651 | 0.90 | ALDH1A1 (0.41) | L3MBTL1DDB1CRBNALDH1A1HPGD | |
| SCHEMBL13167679 | 0.89 | L3MBTL1 (0.41) | L3MBTL1DDB1CRBNALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL4931975 | 0.89 | ALDH1A1 (0.41) | L3MBTL1DDB1CRBNALDH1A1CYP1A2 | |
| SCHEMBL3592613 | 0.89 | DDB1 (0.39) | L3MBTL1DDB1CRBNALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL2910258 | 0.88 | L3MBTL1 (0.41) | L3MBTL1DDB1CRBNALDH1A1HPGD | |
| SCHEMBL4937675 | 0.87 | NPSR1 (0.43) | L3MBTL1DDB1CRBNALDH1A1HPGD | |
| SCHEMBL5478671 | 0.86 | ALDH1A1 (0.43) | L3MBTL1DDB1CRBNALDH1A1HPGD | |
| SCHEMBL2918755 | 0.86 | ALDH1A1 (0.41) | L3MBTL1DDB1CRBNALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240651-A1 | WATER-SOLUBLE THALIDOMIDE DERIVATIVES | ZHANG HESHENG | 2010-09-23 | — | — | US | disclosed |
| US-20100240651-A1 | WATER-SOLUBLE THALIDOMIDE DERIVATIVES | ZHANG HESHENG | 2010-09-23 | — | — | US | disclosed |
| US-20100240651-A1 | WATER-SOLUBLE THALIDOMIDE DERIVATIVES | ZHANG HESHENG | 2010-09-23 | — | — | US | disclosed |
| EP-1607394-B1 | WATER-SOLUBLE THALIDOMINE DERIVATIVES | TIAN JIN HEMAY BIO TECH CO LTD (CN) | 2010-09-01 | — | — | EP | disclosed |
| US-7741342-B2 | Water-soluble thalidomine derivatives | Zhang, Hesheng (CN) | 2010-06-22 | — | — | US | disclosed |
| US-20060094730-A1 | having increased bioavailability when administered orally or by injection; used for treating erythema, behcet's syndrome, crohn's disease, rheumatoid arthritis, abnormal myeloidosis syndrome and tumors | ZHANG, HESHENG (CN) | 2006-05-04 | — | — | US | disclosed |
| EP-1607394-A1 | WATER-SOLUBLE THALIDOMINE DERIVATIVES | Tian Jin Hemay Bio-Tech Co., Ltd. (DE) | 2005-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240651-A1 | WATER-SOLUBLE THALIDOMIDE DERIVATIVES | CCNH, CBR1, CBR3 | L3MBTL1 1405/4885DDB1 2271/4885CRBN 5/4885 |
| US-20060094730-A1 | having increased bioavailability when administered orally or by injection; used for treating erythema, behcet's syndrome, crohn's disease, rheumatoid arthritis, abnormal myeloidosis syndrome and tumors | FCGRT, MALT1, IL1R1 | L3MBTL1 3605/4885DDB1 1471/4885CRBN 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.